Last reviewed · How we verify
NCT05523648
Clinical Effects of Ganshuang Combined TDF to Treat CHB and NAFLD
EARLY_PHASE1 trial testing Chronic Hepatitis B in Chronic Hepatitis B in 92 participants. Completed in 21 December 2021.
20 December 2021
Quick facts
| Lead sponsor | Sichuan Leshan Traditional Chinese Medicine Hospital |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 92 |
| Start date | 5 January 2020 |
| Primary completion | 20 December 2021 |
| Estimated completion | 21 December 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- Chronic Hepatitis B — full drug profile →
Conditions studied
- Chronic Hepatitis B — all drugs for Chronic Hepatitis B →
- Nonalcoholic Fatty Liver Disease — all drugs for Nonalcoholic Fatty Liver Disease →
Sponsor
Sichuan Leshan Traditional Chinese Medicine Hospital
Who can join
Adults 20 to 55, any sex, with Chronic Hepatitis B or Nonalcoholic Fatty Liver Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The changes in liver function, body mass index, controlled attenuation parameters, liver stiffness and HBV-DNA at different time points in each group before and after treatment were counted to explore the clinical efficacy of Ganshuang granules combined with tenofovir in the treatment of CHB complicated with NAFLD.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Targeted modulation of gut microbiota by traditional Chinese medicine and natural products for liver disease therapy.
Zhu LR, Li SS, Zheng WQ, Ni WJ, et al · · 2023 · cited 41× · PMID 36817459 · DOI 10.3389/fimmu.2023.1086078 -
Clinical study of ganshuang granule combined with tenofovir in the treatment of chronic hepatitis B complicated with nonalcoholic fatty liver disease.
Su C, Yang Q. · · 2022 · cited 2× · PMID 36588741 · DOI 10.3389/fphar.2022.1032789
Verify or expand the search:
- PubMed search for NCT05523648
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Chronic Hepatitis B
Currently open trials in the same condition.
- NCT07275918 — SA1211 Injection Phase 1 Study · Phase 1 · recruiting
- NCT04843852 — TLR-9 Adjuvanted Vaccination for Chronic Hepatitis B · Phase 1 · recruiting
- NCT07135349 — A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNα for the Treatment of Hepatitis B · Phase 2 · active not recruiting
- NCT07307586 — A Small Sample Prospective Clinical Study of Azvudine Tablets to Promote Clinical Cure in Patients With Chronic Hepatiti · Phase 3 · recruiting
- NCT07246889 — Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE) · Phase 3 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05523648 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sichuan Leshan Traditional Chinese Medicine Hospital
- Last refreshed: 31 August 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05523648.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing